摘要
目的探讨多发性骨髓瘤(MM)患者骨髓CD14^+CD16^+单核细胞表达水平及其临床意义。方法采用流式细胞术检测多发性骨髓瘤、冒烟型骨髓瘤、淋巴浆细胞淋巴瘤/华氏巨球蛋白血症、意义未明的单克隆免疫球蛋白血症患者和对照组的骨髓CD14^+CD16^+单核细胞表达水平,统计并分析结果差异。结果多发性骨髓瘤患者骨髓CD14^+CD16^+单核细胞水平(%)明显高于冒烟型骨髓瘤、淋巴浆细胞淋巴瘤/华氏巨球蛋白血症、意义未明的单克隆免疫球蛋白血症及对照组,差异均有统计学意义(P<0.05);多部位骨质破坏多发性骨髓瘤患者的CD14^+CD16^+单核细胞比例(%)明显高于单部位骨质破坏的患者,差异有统计学意义(P<0.05)。结论骨髓CD14^+CD16^+表达水平检测可用于判断多发性骨髓瘤的溶骨病变的严重程度及其与相关疾病的鉴别诊断。
Objective To determine the levels of bone marrow CD14＋CD16＋ monocyte in patients with multiple myeloma and explore its clinical significance. Methods The levels ofCD14＋CD16＋ monocytes of bone marrow samples from MM, SMM, LPL/WM, MGUS patients and healthy controls were determined by flow cytometry, and the results were analyzed. Results The level of CD14＋CD16＋ monocytes in patients with active multiple myeloma was higher than that in those with smoldering myeloma, LPL/Waldenstrom macroglobulinemia, MGUS, and the healthy controls, and the differences were statistically significant（P 〈 0.05） ; the level of CD14＋CD16＋ monocytes in patients with multiple myeloma of multiple bone destruction was higher than that in patients with single site bone destruction, and the difference was statistically significant （P 〈 0. 05）. Conclusion The detection of bone marrow CD14＋CD16＋ monocytes level can be used to determine the severity of oateolytic lesions in multiple myeloma and used in the differential diagnosis of related diseases.
出处
《中国卫生检验杂志》
CAS
2018年第8期952-954,共3页
Chinese Journal of Health Laboratory Technology
基金
2014年湖州市科技局科研项目(A类)(2014GYB14)
